MarketCapExport financials
TransMedics Group (TMDX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
TransMedics Group Income Statement 2025-2011 | TMDX
Brief overview of profit and loss at TransMedics Group
This overview is based on financial performance over the past five years. TransMedics Group reported revenue of $25.6 million in 2020 and $605 million by 2025. The cumulative result was +2261.6%, corresponding to roughly 88.2% per year. Sales grew at a rate typical of a strong expansion phase.
Gross profit changed from 16.6 million dollars to 363 million dollars (+2081%). Direct costs outpaced revenue, limiting the benefit of changes in sales. Gross margin moved from 64.9% to 59.9%. A lower margin indicates deterioration in the economics of the core business.
EBITDA was −$24.8 million at the beginning and $136 million at the end of the period (+647.3%). Changes in revenue did not translate into comparable EBITDA performance. The EBITDA share of revenue changed from −96.8% to 22.4%. The business generated more EBITDA from each unit of revenue.
The final result was −$28.7 million initially and $190 million in the final year. The business moved out of a loss and ended the period with a profit.
The five-year change in capitalization reached +733.9%: from $563 million to $4.7 billion. The share-price trend was broadly consistent with improving results.
Conclusion
The figures do not all move in the same direction. The positive side is supported by improving net profitability, sales growth and higher operating efficiency. The most visible risks are a lower gross margin. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement TransMedics Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
4.69 B | 2.45 B | 2.89 B | 2.22 B | 438 M | 563 M | 281 M | - | - | - | - | - | - | - | - |
Shares |
34 M | 33.2 M | 32.5 M | 29.6 M | 27.6 M | 24.7 M | 14.2 M | - | - | - | - | - | - | - | - |
Historical Prices |
138 | 73.7 | 88.9 | 75.2 | 15.9 | 22.8 | 17.5 | - | - | - | - | - | - | - | - |
Net Income |
190 M | 35.5 M | -25 M | -36.2 M | -44.2 M | -28.7 M | -33.5 M | -23.8 M | -20.8 M | -24.1 M | - | - | - | - | - |
Revenue |
605 M | 442 M | 242 M | 93.5 M | 30.3 M | 25.6 M | 23.6 M | 13 M | 7.68 M | 6.21 M | - | - | - | - | - |
Cost of Revenue |
243 M | 179 M | 87.5 M | 28.2 M | 9.1 M | 9 M | 9.74 M | 7.28 M | - | - | - | - | - | - | - |
Gross Profit |
363 M | 262 M | 154 M | 65.3 M | 21.2 M | 16.6 M | 13.9 M | 5.73 M | 2.14 M | 766 K | - | - | - | - | - |
Operating Income |
109 M | 37.5 M | -28.7 M | -31.4 M | -39.4 M | -26.4 M | -29.6 M | -20.2 M | - | - | - | - | - | - | - |
Interest Expense |
- | - | 10.8 M | 3.73 M | 3.87 M | 3.98 M | 4.35 M | 2.72 M | - | - | - | - | - | - | - |
EBITDA |
136 M | 57.3 M | -20.6 M | -28 M | -37.6 M | -24.8 M | -28.4 M | -19.5 M | -19.8 M | -22.6 M | - | - | - | - | - |
Operating Expenses |
254 M | 225 M | 183 M | 96.7 M | 60.6 M | 43 M | 43.5 M | 26 M | 22.6 M | 23.8 M | - | - | - | - | - |
General and Administrative Expenses |
185 M | 169 M | 120 M | 69.9 M | 38.3 M | 24.2 M | 23.6 M | 12.3 M | 7.61 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement TransMedics Group
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
34.6 M | 34.4 M | 34.3 M | 34.1 M | 33.9 M | 33.7 M | 33.6 M | 33.4 M | 33.1 M | 32.8 M | 32.7 M | 32.6 M | 32.5 M | 32.3 M | 32.1 M | 30.2 M | 28 M | 28 M | 27.8 M | 27.7 M | 27.6 M | 27.4 M | 27.2 M | 27.2 M | 23.3 M | 21.2 M | 21.2 M | 21.1 M | 13.1 M | 1.42 M | 1.4 M | 1.37 M | 4.69 M | 1.36 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
14.7 M | 7.32 M | - | 24.3 M | 34.9 M | 25.7 M | - | 4.22 M | 12.2 M | 12.2 M | - | -25.4 M | -1 M | -2.64 M | - | -7.43 M | -11.5 M | -10.6 M | - | -13 M | -10.7 M | -7.92 M | -6.31 M | -5.09 M | -8.5 M | -8.85 M | -9.18 M | -8.28 M | -9.2 M | -6.9 M | -7.64 M | -5.1 M | -6.12 M | -4.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
190 M | 174 M | - | 144 M | 157 M | 144 M | - | 109 M | 114 M | 96.8 M | - | 66.4 M | 52.5 M | 41.6 M | - | 25.7 M | 20.5 M | 15.9 M | - | 5.37 M | 8.17 M | 7.05 M | 7.63 M | 7.09 M | 3.39 M | 7.53 M | 6.06 M | 7.2 M | 5.67 M | 4.68 M | 3.54 M | 4.04 M | 2.92 M | 2.52 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
76.8 M | 72.8 M | - | 59.2 M | 60.8 M | 55.3 M | - | 47.9 M | 45 M | 36.9 M | - | 25.8 M | 15.7 M | 12.8 M | - | 7.57 M | 6.17 M | 3.78 M | - | 1.6 M | 2.58 M | 2.24 M | - | 2.05 M | 1.48 M | 2.67 M | - | 2.99 M | 2.33 M | 2.1 M | - | 1.91 M | 1.74 M | 1.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
113 M | 101 M | - | 84.6 M | 96.6 M | 88.2 M | - | 60.8 M | 69.3 M | 60 M | - | 40.7 M | 36.7 M | 28.8 M | - | 18.1 M | 14.4 M | 12.1 M | - | 3.77 M | 5.59 M | 4.81 M | 4.83 M | 5.04 M | 1.91 M | 4.86 M | 3.74 M | 4.22 M | 3.33 M | 2.57 M | 1.5 M | 2.13 M | 1.18 M | 924 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
23.7 M | 13.3 M | - | 23.3 M | 36.6 M | 27.4 M | - | 3.92 M | 12.5 M | 12.4 M | - | -28.3 M | -906 K | -2.09 M | - | -5.54 M | -9.74 M | -9.37 M | - | -11.7 M | -9.87 M | -6.51 M | -5.9 M | -4.61 M | -7.86 M | -8.02 M | -8.69 M | -7.24 M | -7.7 M | -5.96 M | -6.36 M | -3.94 M | -5.16 M | -4.78 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | 3.62 M | 3.6 M | - | 3.59 M | 2.5 M | 1.09 M | - | 787 K | 972 K | 960 K | - | 979 K | 965 K | 952 K | - | 971 K | 1 M | 1.04 M | - | 1.08 M | 1.11 M | 1.09 M | - | 1.08 M | 313 K | 258 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
45.8 M | 25.2 M | - | 43 M | 36.7 M | 33.6 M | - | 4.02 M | 12.6 M | 16.7 M | - | - | - | -802 K | - | -3.35 M | -9.74 M | -8.86 M | - | -10.4 M | -9.87 M | -6.06 M | -5.9 M | -3.46 M | -7.12 M | -7.65 M | -8.69 M | -6.38 M | -7.17 M | -5.72 M | -6.36 M | -3.39 M | -4.82 M | -4.62 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
89.5 M | 87.9 M | - | 61.3 M | 60 M | 60.8 M | - | 56.9 M | 56.8 M | 47.5 M | - | 69 M | 37.6 M | 30.9 M | - | 23.7 M | 24.1 M | 21.5 M | - | 15.5 M | 15.5 M | 11.3 M | - | 9.65 M | 9.77 M | 12.9 M | - | 11.5 M | 11 M | 8.54 M | - | 6.07 M | 6.34 M | 5.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
57.8 M | 63 M | - | 46 M | 44.1 M | 43.6 M | - | 42.7 M | 42.9 M | 36.2 M | - | 30.7 M | 29.4 M | 25 M | - | 16.9 M | 17.4 M | 13.9 M | - | 10.3 M | 9.16 M | 6.79 M | - | 5.49 M | 5.87 M | 6.65 M | - | 6.52 M | 6.25 M | 4.65 M | - | 2.8 M | 2.9 M | 2.24 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company TransMedics Group (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Curacao
USA
Canada
Israel
Britain
